From participating in a fundraiser on the longest day of the year, to sporting purple gear and sharing stories, supporters are marking Alzheimer’s & Brain Awareness Month, as they do each June. The purpose is to raise awareness among the general public, as well as among policymakers, public authorities,…
In a few days, the U.S. Food and Drug Administration (FDA) is expected to announce whether or not it decided that aducanumab, an investigational treatment for Alzheimer’s disease developed by Biogen, merits approval and wide…
ProMIS Neurosciences will advance the development of PMN310, its manmade antibody designed to target the toxic forms of amyloid beta that underlie Alzheimer’s disease. The first step in the manufacturing of PMN310 will be carried out by Selexis with its proprietary CHO-K1 cell line, part of the company’s…
The Alzheimer’s Association and its advocacy affiliate, the Alzheimer’s Impact Movement (AIM), are backing recently introduced bipartisan legislation to support equity in Alzheimer’s disease clinical trials. The Equity in Neuroscience and Alzheimer’s Clinical Trials (ENACT) Act of 2021 (H.R. 3085/S. 1548) would amend the Public Health…
Brown University is establishing the Center for Alzheimer’s Disease Research to build a world-class research program that is focused on the early detection and treatment of Alzheimer’s disease and related disorders. The center is made possible by separate gifts of $25 million and $5 million from donors who wish…
Annovis Bio is seeking orphan drug status for its investigational therapy ANVS401, known as Posiphen, for treating Alzheimer’s disease in people with Down syndrome (DS-AD). The clinical-stage drug platform company has filed an application with the U.S. Food and Drug Administration (FDA) for such designation, granted to therapies for…
A $10.7-million grant to investigate the genetic underpinnings of Alzheimer’s disease has been awarded to the University of Pittsburgh Graduate School of Public Health and Washington University School of Medicine in St. Louis. Despite years of research, scientists have yet to come up with a cure for Alzheimer’s disease…
A draft report from the Institute for Clinical and Economic Review, known as ICER, found that there is insufficient evidence to determine whether the investigational therapy aducanumab will provide health benefits to people with Alzheimer’s disease. ICER is an independent non-profit research institute that works to assess the…
Longeveron’s Lomecel-B, an investigational bone marrow-derived medicinal signaling cell (MSC), showed an ability to slow cognitive decline and the loss of daily life abilities in patients with mild Alzheimer’s disease relative to those given a placebo in a Phase 1 clinical trial, the company announced. Treatment with Lomecel-B was deemed safe,…
LX1001, a gene therapy for Alzheimer’s disease being developed by Lexeo Therapeutics, has been granted fast track designation by the U.S. Food and Drug Administration (FDA). The therapy is designed to deliver a version of the APOE gene, called APOE2, to cells in the central nervous system (the…
Get regular updates to your inbox.